Pharmalot By Ed Silverman Two dozen states side with HHS in its raucous dispute with pharma over a drug discount program
Pharmalot By Ed Silverman Greece plans to go to court to seek compensation from Novartis over a bribery scandal
Exclusive By Nicholas Florko Senate FDA legislation will include dietary supplement, cosmetic reforms
First Opinion By Billy Kenber The man behind ‘value-based pricing’ saw pharma distorting his message — and walked away
Pharmalot By Ed Silverman National Institutes of Health licenses nearly a dozen Covid-19 technologies to a WHO program
Biotech By Adam Feuerstein Roche anti-TIGIT cancer immunotherapy fails second clinical trial, raising doubts about drug class
Pharmalot By Ed Silverman Drugmakers win court battle over an HHS rule that would have penalized them for offering copay coupons
First Opinion By Paul Fenyves Does Paxlovid help people who have been vaccinated against Covid-19? Show us the data!
Pharmalot By Ed Silverman Drugmakers use monopoly tactics to thwart lower-cost generic competition for inhalers, analysis finds
Pharmalot By Ed Silverman High blood pressure pills are costly — but also hard to find — in some lower-income countries
Pharmalot By Ed Silverman Pharmalittle: FDA OKs new type of diabetes drug from Lilly; Early-stage biotechs are juicy targets for M&A surge
Pharmalot By Ed Silverman Why a controversial patent rights waiver could be a ‘missed opportunity’ to tackle the next pandemic
First Opinion By Brian Barnett Flawed FDA safety requirements are hamstringing a highly effective treatment for severe schizophrenia
Health Tech By Mohana Ravindranath A clash over online Adderall prescriptions is raising new questions about telehealth
Pharmalot By Ed Silverman California fines an OptumRx pharmacy for jeopardizing patient health. Is that enough?
Health By Matthew Herper Biden administration starts Covid treatment push, focusing on Pfizer’s Paxlovid
Pharmalot By Ed Silverman U.S. spending on pharmaceuticals jumped 12% in 2021, fueled by costs of Covid-19 vaccines and therapies
Opinions+ By Scott Swain, Kristin M. Zimmerman Savill and Bruce Feinberg Pharma’s role in value-based care starts with value-based research
First Opinion By Bernard Zipprich Will the shadow of Aduhelm cloud FDA’s decision-making on an ALS therapy?
Pharmalot By Ed Silverman Endo wins a reprieve in an opioid lawsuit in Tennessee as appeals court overturns sanctions
Pharmalot By Ed Silverman Bristol Myers agrees to settle lawsuit alleging anti-competitive deals involving HIV drugs
Biotech By Jonathan Wosen Halozyme to acquire Antares for nearly $1B in bid to dominate drug delivery market
Biotech By Adam Feuerstein Good fortunes continue for Sierra Oncology with $1.9 billion acquisition by U.K. pharma giant Glaxo
Pharmalot By Ed Silverman Pharma pledges faster drug launches in Europe in hopes of avoiding stricter regulations